Kamada Ltd. is a vertically integrated biopharmaceutical company focused on specialty plasma-derived therapeutics for rare and serious conditions. The company operates through two main segments: Proprietary Products, which includes FDA-approved therapies such as KEDRAB, GLASSIA, CYTOGAM, WINRHO SDF, VARIZIG, and HEPAGAM B, as well as KAMRAB and equine-based anti-snake venom products; and Distribution, which involves the commercialization of in-licensed third-party biopharmaceuticals and biosimilars in Israel. Kamada manufactures its products at a cGMP facility in Beit Kama, Israel, and operates plasma collection centers in the United States to supply normal source plasma and hyper-immune plasma. The company distributes its portfolio directly and through partners in the U.S., Canada, Israel, Russia, Brazil, Argentina, India, and other regions in Latin America and Asia. Founded in 1990, Kamada is listed on the Nasdaq and the Tel Aviv Stock Exchange. Key partnerships include supply and distribution agreements with Kedrion and Takeda, and a collaboration with Alvotech for biosimilar distribution in Israel.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage kamada.com
Sector Healthcare IR page kamada.com/investor-resources
Tags
plasma-derived therapeutics, hyperimmune globulins, alpha-1 antitrypsin deficiency, rabies prophylaxis, biosimilars, plasma collection, rare diseases, specialty pharmaceuticals, anti-snake venom, KEDRAB, GLASSIA, CYTOGAM, WINRHO SDF, VARIZIG, HEPAGAM B, KAMRAB, KAMRHO (D), Kedrion, Takeda, Alvotech, FIMI Opportunity Fund, PARI
Press page kamada.com/news

Metrics

Valuation  
Market cap $ 488.024M
Market cap (USD) $ 488.024M
P/E 19.23
PEG —
P/BV 1.82
P/S 2.70
P/OCF 19.15
P/FCF 21.25
Dividend yield —
Turnover / mcap —
Returns  
ROE 7.6%
ROI 7.2%
ROIC 8.1%
Profit margin 11.2%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score 5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 180.46M 10B 142.519M 129.339M 103.642M 133.246M 127.187M 114.469M 102.825M 77.494M 69.906M 71.065M 70.623M 72.675M
Net profit 20.198M 14.462M 8.284M -2.321M -2.23M 17.14M 22.251M 22.296M 6.901M -6.733M -11.27M -13.213M 443K 260K
Free cash flow 22.967M 36.854M -1.535M 24.802M -12.549M 18.383M 26.579M 9.826M 1.927M — -16.697M -9.928M -9.497M -12.871M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 7.06 6.09 6.12 4.01 6.58 6.48 6.83 5 4.75 5.45 4.15 3.78 14.87 —
Price performance 12m 0.16 -0 0.53 -0.39 0.02 -0.05 0.37 0.05 -0.13 0.31 0.1 -0.75 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 19.8M — — — — — — — — —
↳ YoY growth -14.2%
Borrowings, non-current (USD) 1.36M — — — — — — — — —
Cash and deposits (USD) 9.97M — — — — — — — — —
Net debt (borrowings + leases - cash) (USD) -8.6M — — — — — — — — —
Cash flow detail
Operating cash flow (USD) 1.9M — — — — — — — — —
Purchases of property, plant and equipment (USD) -2.64M — — — — — — — — —
Change in receivables (cash effect) (USD) -3.49M — — — — — — — — —
Change in inventories (cash effect) (USD) -742,000 — — — — — — — — —
Interest paid (cash effect) (USD) -60,000 — — — — — — — — —
Income taxes paid (cash effect) (USD) -1.79M — — — — — — — — —
Operating cash flow before change in receivables (USD) 5.39M — — — — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -744,000 — — — — — — — — —
Income detail
Research and development expense (USD) 16.2M 12M 9.75M 13.1M 13.6M 11.4M 13.2M 13.9M 15.2M 13M
↳ 5y CAGR +6.7% +0.3% -5.2% -4.0% -3.8% -6.9% +1.9% +7.4% +3.1% -0.9%
Total comprehensive income (USD) -6.84M — — — — — — — — —
Comprehensive income to owners (USD) -6.84M — — — — — — — — —
Reported Mar 1, 2017 Mar 6, 2018 Feb 27, 2019 Feb 26, 2020 Feb 24, 2021 Mar 15, 2022 Mar 15, 2023 Mar 6, 2024 Mar 5, 2025 Mar 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Dividend to be Paid Consistent with the Company’s Cash Dividend Policy

REHOVOT, Israel, and HOBOKEN, NJ – November 9, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that its Board of Directors has declared a cash dividend of $0.14 (approximately NIS 0.45) per share on the Company’s ordinary shares (totaling approximately $8.0 million). The cash dividend will be payable on December 9, 2026, to shareholders of record at the close of business on November 19, 2026. The dividend payment is consistent with the Company’s dividend policy.

“Based on the Company’s record-high financial results for the first nine months of 2026 and our solid cash position, we are pleased to announce another cash dividend to be paid to our shareholders,” said Amir London, Kamada’s Chief Executive Officer. “This dividend payment is in addition to the $24.2 million dividend payments made earlier this year.

Company to Host Conference Call at 8:30am ET

REHOVOT, Israel, and HOBOKEN, NJ – November 2, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2026, prior to the open of the U.S. financial markets on Monday, November 9, 2026.

Kamada’s management will host an investment community conference call on Monday, November 9, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 13763380. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1779441&tp_key=96a5dea210.

About Kamada

Kamada Ltd.

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate approximately $10 Million in Annual Revenue in 2028 and approximately $20 Million-$25 Million in Annual Revenue by 2030

REHOVOT, Israel, and Hoboken, NJ, – October 6, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products.

The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara®, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane®, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings.

The launch of the new products is in addition to the Company’s first two biosimilar products Bevacizumab-Kamada, a biosimilar to Avastin® (Bevacizumab), and Pegfilgrastim-Kamada, a biosimilar to Neulasta®, which were launched in the Israeli market over the last two years. The Company expects the commercial availability of at least two additional biosimilar products during 2027.
All four biosimilar products were approved and launched as interchangeable with the reference original biologic product.

Kamada’s existing commercial portfolio of biosimilars is anticipated to generate approximately $4 million in sales in 2026, growing to approximately $10 million in 2028. By 2030 the Company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa (MENA) region, with the expectation to generate between approximately $20 million to $25 million in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.

“Kamada is building a growing and diversified biosimilars portfolio across key therapeutic areas. Our biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region make us an attractive in-licensing partner, and we are pleased to have launched two additional biosimilars,” said Amir London, Kamada’s Chief Executive Officer. “The growth of our biosimilar product portfolio is one of our key strategic growth pillars. We continue to evaluate additional licensing opportunities that offer attractive commercial potential, and we expect this portfolio to become a meaningful contributor to our overall annual revenue growth in the years ahead.”

**About Kamada
**Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

**Cautionary Note Regarding Forward-Looking Statements
**This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) the expected expansion, composition and geographic reach of Kamada’s biosimilar product portfolio; 2) the anticipated timing of the commercial availability and launch of additional biosimilar products; 3) the expected sales and annual revenue contribution of Kamada’s biosimilar product portfolio, including the anticipated generation of approximately $4 million in sales in 2026, approximately $10 million in sales in 2028 and approximately $20 million–$25 million in annual revenue by 2030; 4) the expected number of marketed biosimilar products and licensing partners by 2030; 5) the development or registration status of additional licensed biosimilar products and their potential contribution to further portfolio expansion; 6) Kamada’s ability to leverage its biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region to remain an attractive in-licensing partner and to identify, evaluate, enter into and successfully commercialize additional in-licensing opportunities that offer attractive commercial potential; and 7) the anticipated contribution of Kamada’s biosimilar product portfolio to its future annual revenue growth, including the expectation that the portfolio will become a meaningful contributor to such growth in the years ahead. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the effect of tariffs on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada’s ability to find business development and M&A transactions and leverage such opportunities and successfully integrate such opportunities with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov . The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

 CONTACTS**:
**Chaime Orlev
Chief Financial Officer
[email protected]

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
[email protected]

Join Our Mailing List

Sign up to receive Email updates from Kamada

Company Presentation

See the company’s updated presentation

This website uses cookies to track the site’s performance and improve user experience.

By using our website you consent to all cookies in accordance with our Privacy Policy .

I Agree

Prompts

Kamada Ltd. (ticker KMDA), listed in United States.

ETFs Holding Kamada Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.01% 55,275 $ 449.386K Nov 12, 2026
DFIS 0.01% 41,632 $ 338.468K Nov 12, 2026
DFIC 0.00% 35,802 $ 291.07K Nov 12, 2026
DFAX 0.00% 13,239 $ 107.633K Nov 12, 2026